Sign In
NewsRadar

Mission Therapeutics

The company is developing a platform of technologies for the discovery and development of modulators of enzymes involved in cancer and other diseases.

• Show past press releases
• Edit this company

Contact Information
Address:
 
 

Phone:
Web:
Contact:
 
 
Meditrina (Building 260)
Babraham Research Campus
Cambridge CB22 3AT
United Kingdom
+ 44 (0)1223 497454
http://missiontherapeutics.com
Niall Martin
+ 44 (0)1223 497454

Company Facts
Founded:Dec 2010
Founders:Niall Martin , Steve Jackson, Xavier Jacq, Keith Menear
CEO:Niall Martin
CTO or technical lead:Steve Jackson
CFO or finance director:
Head of Sales:
Head of Marketing:

Stage:
Category:Biotechnology & Healthcare
Sector:Biopharmaceuticals
Employees:
Profitability:
Funding raised:Yes
Funding sought:
Seeking Partnerships:

Non-executive Board Members

Key Customers

Key Business Partners

Key Competitors

Capital Raised
DateSizeInvestors
To view this information you must be signed in and subscribed to the online dataservice, sign in here.

To read more about the Online data service click here

Public Offerings
DateTypeExchange
No public offerings


Data


26,673
Tech investments
From our Online Data Service
17,217
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Feb 14€19.0MBiopharmaceuticals
Feb 14N/AInternet services
Feb 14€4.6MBusiness applications
Feb 13€13.0MBiopharmaceuticals
Feb 13€25.0MMedical devices
Feb 13€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase





About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.